{'fraction_non_alphanumeric': 0.03913894324853229, 'fraction_numerical': 0.0273972602739726, 'mean_word_length': 4.879310344827586, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
[Parkinson disease and asthenic syndrome].

AIM
To study the clinical heterogeneity of fatigue syndrome and evaluate the efficacy of cytoflavin as an addition to standard treatment in patients with Parkinson's disease.


MATERIAL AND METHODS
One hundred patients with Parkinson's disease and fatigue took part in the study, 59 patients continued to participate in the study including 59.3% (32) women and 40.7% (27) men. All patients received standard treatment. The equivalent daily dose of levodopa (LEDD) was 736.9±419.1 mg/day. The average age of patients was 67±8.6 (from 65 to 85 years). Cytoflavin was used as an additional therapy in the standard dosage. All patients underwent neuropsychological examination for an estimate of the rate of fatigue, depression, health status, activity, mood and quality of life.


RESULTS AND CONCLUSION
Cytoflavin is well tolerated by patients with Parkinson's disease and fatigue syndrome at the standard dosage. It improves the health, mood, quality of life and reduces fatigue.